OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS Share Price
Certificat
DE000SF7UWG6
| Market Closed - Deutsche Boerse AG 20:37:34 24/05/2024 BST | ||
| 26.4 EUR | +1.54% |
|
| Current month | +24.88% | ||
| 1 month | +21.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 26.4 | +1.54% |
| 23/05/24 | 26 | +1.72% |
| 22/05/24 | 25.56 | +2.16% |
| 21/05/24 | 25.02 | -1.81% |
| 20/05/24 | 25.48 | +0.63% |
Delayed Quote Deutsche Boerse AG
Last update May 24, 2024 at 08:37 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF7UWG |
| ISIN | DE000SF7UWG6 |
| Date issued | 18/08/2021 |
| Strike | 169.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.22 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.4 € |
|---|---|
| Lowest since issue | 3.21 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457
USD
Average target price
462.8
USD
Spread / Average Target
+1.28%
- Stock Market
- Certificates
- Certificat
